COVID-19 And Patients Undergoing Pharmacological Treatments For Immune-Mediated Inflammatory Diseases: Protocol For A Rapid Living Systematic Review
Rocha, A. P.; Atallah, A. N.; Pinto, A. C. P. N.; Rocha Filho, C. R.; Reis, F. S. d. A.; Milby, K. M. M.; Civile, V. T.; Carvas Junior, N.; Santos, R. R. P.; Ferla, L. J.; Trevisani, G. F. M.; Ramalho, G. S.; Puga, M. E. d. S.; Trevisani, V. F. M.
Show abstract
CONTEXT AND OBJECTIVEWe propose to systematically review the available evidence to evaluate if patients with immune mediated inflammatory diseases under pharmacological treatment with immunosuppressants, immunobiologics, Disease-Modifying Anti-Rheumatic Drugs (DMARD) or targeted synthetic DMARDs have better or worse outcomes when infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This study is a protocol for our rapid living systematic review. METHODS: Protocol for a rapid living systematic review methodology following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidance. To conduct the rapid systematic review, we will employ abbreviated systematic review methods, including: not performing independent screens of abstracts and not searching grey literature. As this will be a living review, it will be continuously updated.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.